基于关联规则和复杂系统熵聚类研究历代原发性肝癌方剂遣药组方规律
Analysis on the Principles of Primary Liver Cancer Prescriptions Based on Association Rules and Entropy Clustering of Complex Systems
摘要: 目的:我国是肝癌大国,自秦汉起就有对其症状的描述和用药的记载。本研究基于历代医案,揭示自秦汉至现代治疗原发性肝癌内服方剂的遣药组方规律。方法:收集《中医方剂大辞典》自秦汉至现代治疗原发性肝癌相关的方剂727首,涉略医书235本,运用中医传承辅助系统(V2.5)中关联规则和复杂系统熵聚类分析历代肝癌用药遣药组方规律;通过大数据挖掘和比对,发现治疗原发性肝癌的新处方。结果:历代肝癌用药频次前30味中药以甘草、陈皮、茯苓、当归、木香为主,158个常用药对以陈皮–甘草、黄芩–甘草、陈皮–茯苓和甘草–柴胡为主,36个核心组合以三棱–莪术–青皮为主,以及以柴胡类方为主的8个演化新方。结论:历代肝癌用药体现了原发性肝癌多以脏腑气血亏虚为主,夹杂湿、热、痰、瘀等实证的病机特点,用方侧重于柴胡类方,旨在条达肝气、和解少阳、疏利三焦,为现代临床治疗肝癌用药思想及新药研发提供了一定的理论依据,以期指导临床遣药组方并推进中医肝癌的精准治疗。
Abstract: Objective: Primary liver cancer (PLC) is an aggressive malignancy with increasing mortality in China. The description of PLC symptoms and treatment has been recorded from the Qin-Han Dy-nasty. The aim of present study is to reveal the principles of the PLC internal prescriptions from Qin-Han Dynasty to nowadays according to the medicinal records. Method: 727 prescriptions of the PLC treatment from Qin-Han Dynasty to nowadays were collected in the Dictionary of Chinese Medicine Prescription (DCMP), containing 235 medical books. The methods of Association Rules and Entropy Clustering of Complex Systems and data mining from TCM Inheritance Support System (V2.5) approached to analyze the prescription principles of PLC and to identify new prescriptions for the PLC treatment, respectively. Results: The top 30 herbs used in the PLC treatment frequency were mainly related to Gan Cao, Chen Pi, Fu Ling, Dang Gui, Mu Xiang, etc. 158 commonly used herb pairs were mainly associated with Chen Pi-Gan Cao, Huang Qin-Gan Cao, Chen Pi-Fu Ling, and Gan Cao-Chai Hu, etc. The core of 36 combinations is San Leng-E Zhu-Qing Pi. 8 evolved new prescriptions look like a party of Chai Hu Decoction. Conclusion: The medications of PLC treatment in the past days reflected the pathogenic characteristics of PLC, which is response to the deficiency of qi and blood, interspersed with actual symptoms such as dampness, heat, phlegm, and stasis. The prescriptions focused on Chai Hu decoction, which aims to promote liver qi, reconcile Shao Yang and regulate Sanjiao. It provides the theoretical evidence for how to correctly use TCM and new prescriptions development for the PLC treatment, leading to guide clinical prescriptions and promote the progress of precision treatment of PLC in TCM.
文章引用:乔曦, 许世豪, 朱紫依, 李姚婷, 彭佩克, 王梦琳, 徐琎, 沈凯凯. 基于关联规则和复杂系统熵聚类研究历代原发性肝癌方剂遣药组方规律[J]. 中医学, 2021, 10(4): 516-527. https://doi.org/10.12677/TCM.2021.104070

参考文献

[1] Stepien, M., Fedirko, V., Duarte-Salles, T., et al. (2016) Prospective Association of Liver Function Biomarkers with Development of Hepatobiliary Cancers. Cancer Epidemiology, 40, 179-187.
[2] 王伟进, 张晓路. 中国癌症的现状与疾病负担[J]. 中国经济报告, 2019(4): 63-73.
[3] 李佳红, 付娜, 牛学敏, 焦冠楠, 南月敏. 573例原发性肝癌病因及临床特点分析[J]. 实用肝脏病杂志, 2015, 18(4): 399-402.
[4] 周勇, 唐万和. 中晚期原发性肝癌的中医临床研究[J]. 湖北中医杂志, 2013, 35(7): 45-47.
[5] 孙佳, 叶丽红. 名老中医治疗肝癌经验研究评述[J]. 中医学报, 2012, 27(6): 658-660.
[6] 唐仕欢, 申丹, 卢朋, 等. 中医传承辅助平台应用评述[J]. 中华中医药杂志, 2015, 30(2): 329-331.
[7] 杨洪军, 赵亚丽, 唐仕欢, 等. 基于熵方法分析中风病方剂中药物之间的关联度[J]. 中国中医基础医学杂志, 2005, 11(9): 706.
[8] 唐仕欢, 陈建新, 杨洪军, 等. 基于复杂系统熵聚类方法的中药新药处方发现研究思路[J]. 世界科学技术-中医药现代化, 2009, 11(2): 225.
[9] Yang, H.J., Chen, J.X., Tang, S.H., et al. (2009) New Drug R&D of Traditional Chinese Medicine—Role of Data Mining Approaches. JBS, 17, 1. [Google Scholar] [CrossRef
[10] 武嫣斐, 王素萍, 孙健民, 魏俊妮. 原发性肝癌中医证型临床分布及证型标准[J]. 山西中医学院学报, 2007, 8(2): 21-23.
[11] Cheng, Y., Chen, T., Yang, X., et al. (2019) Atractylon Induces Apoptosis and Suppresses Metastasis in Hepatic Cancer Cells and Inhibits Growth in Vivo. Cancer Management and Research, 11, 5883-5894. [Google Scholar] [CrossRef
[12] Xi, S., Peng, Y., Minuk, G.Y., et al. (2016) The Combination Effects of Shen-Ling-Bai-Zhu on Promoting Apoptosis of Transplanted H22 Hepatocellular Carcinoma in Mice Receiving Chemotherapy. Journal of Ethnopharmacology, 190, 1-12. [Google Scholar] [CrossRef] [PubMed]
[13] Tang, Z.H., Li, T., Chang, L.L., et al. (2014) Glycyrrhetinic Acid Triggers a Protective Autophagy by Activation of Extracellular Regulated Protein Kinases in Hepatocellular Carcinoma Cells. Journal of Agricultural and Food Chemistry, 62, 11910-11916. [Google Scholar] [CrossRef] [PubMed]
[14] Yu, M., Yu, X., Guo, D., et al. (2015) Ginsenoside Rg1 Attenuates Invasion and Migration by Inhibiting Transforming Growth Factor β1-Induced Epithelial to Mesenchymal Transition in HepG2 Cells. Molecular Medicine Reports, 11, 3167-3173. [Google Scholar] [CrossRef] [PubMed]
[15] 李兰英, 彭蕴汝, 钱士辉. 陈皮多甲氧基黄酮类成分诱导荷H22肝癌小鼠肿瘤细胞凋亡作用的研究[J]. 中药材, 2009, 32(10): 1596-1598.
[16] 王巧玲, 贾绍华. 川陈皮素抗癌作用及机制的研究进展[J]. 中草药, 2009, 40(S1): 40-42.
[17] 苗加伟, 陈洁, 邓雪松, 熊书, 李国利, 马强. 去氢木香内酯抑制人肝癌细胞系HepG2增殖及促凋亡[J]. 基础医学与临床, 2020, 40(10): 1369-1373.
[18] 卢新兰, 卢朝辉, 曹琰, 张旭, 王新, 李雅睿, 郭丹, 和水祥. 柴胡皂甙D诱导肝癌细胞同时发生凋亡及类凋亡性细胞死亡[J]. 西安交通大学学报(医学版), 2020, 41(6): 966-971.
[19] 舒遵华, 王慧林, 刘扬扬, 杨明, 王珊珊, 来庆娟, 熊壮. 大黄素抗肝癌作用机制的研究进展[J]. 吉林中医药, 2020, 40(2): 278-280.
[20] 林蔚, 潘竞锵, 吕俊华, 肖柳英, 张世平. 栀子抑制小鼠S180和肝癌及促进小鼠肝癌细胞凋亡作用[J]. 中国医疗前沿, 2007(8): 4-6.
[21] 陈建卫, 高娟, 朱忠辉, 宫卫东, 卫飞鹏, 刘晓宇, 李晓冰. 黄连素对肝癌细胞系HepG2细胞体外迁移影响及其机制研究[J]. 陕西医学杂志, 2018, 47(6): 686-689.
[22] 孙政敏. 当归多糖对荷瘤小鼠肿瘤生长和铁代谢的影响[D]: [硕士学位论文]. 新乡: 新乡医学院, 2018.
[23] 张亚武, 权柯. 芍药苷对HepG2肝癌细胞凋亡的诱导作用[J]. 西部中医药, 2016, 29(5): 23-25.
[24] 陈卓. 羧甲基茯苓多糖对在两种肝癌细胞上清液中培养的树突状细胞的成熟及免疫功能影响[D]: [硕士学位论文]. 广州: 暨南大学, 2008.
[25] 郭楠楠. 苍术酮对体外培养肝癌细胞HepG2的抑制作用[J]. 安徽农业科学, 2015, 43(12): 51-53.
[26] 徐大椿. 医学源流论[M]. 万芳, 整理. 北京: 人民卫生出版社, 2007.
[27] 花海兵, 胡燕姣. 中晚期肝癌四大症状皆宜从脾论治[J]. 浙江中医杂志, 1996, 31(12): 555.
[28] 王琦, 周胜强, 刘芳, 刘祖贻. 刘祖贻扶正三法治疗肝癌经验[J]. 中医杂志, 2019, 60(13): 1099-1101.
[29] 陈少丽, 文小平, 陈德兴, 都广礼. 试论“药群法”建立方剂方解的可行性[J]. 上海中医药大学学报, 2017, 31(4): 4-7.
[30] 李明襄, 王海晓, 叶舒婷, 张念栋, 叶蕾. 四君子汤活性成分抗肝癌研究现状[J]. 内蒙古中医药, 2019, 38(12): 141-143.
[31] 江洋. 二陈汤及其加减方通过JNK信号通路抑制NSCLC肿瘤血管生成的实验研究[D]: [硕士学位论文]. 北京: 北京中医药大学, 2019.
[32] 崔亚运, 黄古叶, 陈梓洋, 陈鹏兰. 小柴胡汤防治肝病的实验研究进展[J]. 中医药临床杂志, 2020, 32(1): 190-194.
[33] 杨鹤. 逍遥散加味联合TACE治疗原发性肝癌(肝郁脾虚型)的临床观察[D]: [硕士学位论文]. 南宁: 广西中医药大学, 2018.
[34] 卢冬彦, 叶小卫. 血府逐瘀汤治疗原发性肝癌TACE术后气滞血瘀型疼痛30例[J]. 安徽中医药大学学报, 2016, 35(1): 45-47.
[35] 陈学武, 姜靖雯, 林福煌. 龙胆泻肝汤治疗原发性肝癌TACE术后栓塞综合征的疗效观察[J]. 南京中医药大学学报, 2016, 32(3): 224-228.
[36] 王鑫, 杨洋, 杨兴武. 大柴胡汤治疗肝癌TACE术后综合征的疗效分析[J]. 陕西中医药大学学报, 2019, 42(1): 130-133.
[37] 黄覃凤. 从活血化瘀法论治肝癌复发和转移的理论探讨[J]. 时针国医国药, 2018, 29(8): 1944-1945.
[38] 贾文霞, 赵红兵, 陈桂杰, 等. 肝癌的中医用药方法[J]. 中国中医基础医学杂志, 2017, 23(1): 121-123.
[39] 李朝军, 刘嘉湘. 刘嘉湘教授治疗肝癌经验[J]. 山西中医, 2009, 25(12): 9-10.
[40] 张雯雯, 蒋吟啸, 杨丹, 胡启超, 文建霞, 郭耀光, 曾进浩, 李浩田, 马骁. 小柴胡汤联合经导管动脉栓塞化疗治疗原发性肝癌的有效性与安全性的系统评价[J]. 中国医院用药评价与分析, 2020, 20(2): 149-153+157.
[41] 张承军. 龙胆泻肝汤治疗原发性肝癌TACE术后栓塞综合征疗效观察[J]. 现代中西医结合杂志, 2017, 26(27): 3001-3003.
[42] 覃岭, 赵微, 何峰, 吴维宇. TACE联合中药治疗原发性肝癌伴门静脉癌栓的临床疗效观察[J]. 西部医学, 2019, 31(1): 105-108.
[43] 马立伟. 养阴补肝汤结合TACE治疗原发性肝癌的临床研究[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2017.